Searched over 200M research papers
10 papers analyzed
These studies suggest that losartan reduces the risk of kidney damage, proteinuria, and end-stage renal disease in various populations, while also maintaining cardiovascular health and potentially offering cost savings.
20 papers analyzed
Losartan, an angiotensin-II-receptor antagonist, has shown significant renal benefits in patients with type 2 diabetes and nephropathy. A large-scale study involving 1513 patients demonstrated that losartan reduced the incidence of a doubling of serum creatinine concentration by 25% and end-stage renal disease (ESRD) by 28% compared to placebo, over a mean period of 3.4 years. Additionally, losartan significantly decreased proteinuria levels by 35%, indicating its protective effect on kidney function beyond blood pressure control.
In a study focusing on American Indians with type 2 diabetes, losartan was found to preserve kidney structure in patients with microalbuminuria, although its long-term impact on glomerular filtration rate (GFR) decline was not significantly different from placebo . This suggests that while losartan may offer structural benefits in early diabetic nephropathy, its effect on long-term kidney function requires further investigation.
Losartan helps prevent the imbalance between the renal dopaminergic system (RDS) and the renin-angiotensin system (RAS), which is often disrupted in conditions like insulin resistance and hypertension. In a study with fructose-overloaded rats, losartan corrected metabolic and hemodynamic alterations, reduced pro-inflammatory and pro-fibrotic markers, and prevented renal damage. This highlights losartan's role in modulating renal systems to protect against kidney injury.
Losartan has also been shown to mitigate renal ischemia/reperfusion (I/R) injury, a major cause of acute kidney injury. In rat models, losartan administration before and after I/R significantly reduced serum markers of kidney damage and oxidative stress, suggesting its potential in protecting kidneys from acute injuries.
In a comparative study with amlodipine, another antihypertensive, losartan was more effective in reducing proteinuria in patients with chronic kidney disease (CKD) and hypertension, despite both drugs having similar efficacy in blood pressure control. This indicates that losartan's renoprotective effects extend beyond its antihypertensive properties.
The economic evaluation of the RENAAL study revealed that losartan not only reduced the incidence of ESRD but also resulted in substantial cost savings. By decreasing the number of days patients experienced ESRD, losartan reduced the associated healthcare costs, making it a cost-effective treatment option for diabetic nephropathy.
An interesting observation from the RENAAL trial was that an acute fall in GFR during the initial phase of losartan treatment predicted a slower decline in long-term renal function. This suggests that the initial drop in GFR might reflect a beneficial hemodynamic effect, leading to better long-term kidney outcomes.
While combination therapy with losartan and ACE inhibitors can decrease proteinuria, it also increases the risk of adverse events such as hyperkalemia and acute kidney injury. Therefore, the safety of such combination therapies remains uncertain, and they should be used with caution.
Losartan has demonstrated significant renoprotective effects in various studies, particularly in patients with type 2 diabetes and nephropathy. Its ability to reduce proteinuria, prevent renal damage, and offer economic benefits makes it a valuable treatment option. However, the long-term impact on GFR and the safety of combination therapies require careful consideration. Overall, losartan remains a cornerstone in the management of kidney health, particularly in diabetic patients.
Most relevant research papers on this topic